---
title: "Takeda CHRO Nicola D. Greenway sells 12,980 ADS for $235,173.42"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296395853.md"
description: "Takeda Chief Human Resources Officer Nicola Deidre Petal Greenway sold 12,980 American Depositary Shares (ADS) on August 18, 2026, at $18.11 per share, totaling $235,173.42. Following the transaction, her post-transaction holding stands at 40,049 ADS. The information was published via EDGAR by Takeda Pharmaceutical Co. Ltd."
datetime: "2026-08-19T20:16:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296395853.md)
  - [en](https://longbridge.com/en/news/296395853.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296395853.md)
generator: "portal-rs"
---

# Takeda CHRO Nicola D. Greenway sells 12,980 ADS for $235,173.42

-   Takeda Chief Human Resources Officer Nicola Deidre Petal Greenway sold 12,980 American Depositary Shares on Aug. 18, 2026. \* Shares were sold at $18.11 each. \* Post-transaction holding totaled 40,049 American Depositary Shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-039214), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda and Weave Bio collaborate on AI-driven automation in drug development](https://longbridge.com/en/news/297762467.md)
- [Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO](https://longbridge.com/en/news/297377145.md)
- [Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug](https://longbridge.com/en/news/297545595.md)
- [Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1](https://longbridge.com/en/news/296890461.md)
- [Weekly Recap: MIMRYLO license terms and Orzeyful FDA approval](https://longbridge.com/en/news/297567010.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**